3 reasons to buy Resmed shares like there's no tomorrow

The healthcare major continues to be well positioned, experts say.

| More on:
Man with a sleep apnoea mask on whilst sleeping.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc (ASX: RMD) shares have been a top performer in the ASX healthcare sector so far in 2024.

Currently trading at $32.78 per share, this respiratory care player's stock is up more than 29% since January and 17% in the past twelve months.

It has outperformed the benchmark S&P/ASX 200 Index (ASX: XJO) by more than 9% over the past 12 months, offering a significant advantage.

Here's why experts are bullish on Resmed shares.

Created with Highcharts 11.4.3ResMed PriceZoom1M3M6MYTD1Y5Y10YALL1 Aug 202313 Aug 2024Zoom ▾Sep '23Nov '23Jan '24Mar '24May '24Jul '24Oct '23Oct '23Jan '24Jan '24Apr '24Apr '24Jul '24Jul '24www.fool.com.au

Resmed shares in favour

Experts are bullish on the respiratory device company's stock price for a multitude of reasons, but three common 'themes' emerge amongst analyst opinions.

1. Dominant market position, minimal competition

ResMed holds a dominant position in the sleep disorder treatment market with its devices for treating obstructive sleep apnea (OSA).

Hyperion Asset Management says the business faces little to no credible competition in doing so.

According to my colleague Tristan, the firm points to ResMed as one of five ASX 200 companies that truly have "no credible competition."

This stronghold allows the company to maintain robust margins and sales, helping ResMed shares along the way.

In my view, this is an enduring competitive advantage which could mean Resmed's long-term growth potential remains intact.

2. Financial performance and growth

ResMed's financials are worth noting too. In Q4 FY24, the company reported a 9% increase in revenue, reaching US$1.2 billion.

This growth was underlined by strong demand for its sleep devices and masks, alongside a booming Software as a Service (SaaS) business. Funny – Resmed is behaving a bit like a software company.

Moreover, ResMed's gross margin improved by 350 basis points, leading to quarterly earnings per share (EPS) of US$1.98.

Analysts have taken note of this performance. Morgans rated the stock a buy with a price target of $35.93. It says the business is "remains well placed and uniquely positioned as it builds a patient-centric, connected-care digital platform…".

Macquarie shares this optimism, also rating the stock a buy with the same price target. Both brokers see ResMed's steady growth and robust financials as key reasons for their positive outlook.

3. Resilience in a volatile market

ResMed shares have proven their resilience in volatile share market conditions. While many ASX 200 stocks have struggled so far in FY25, ResMed shares have been buoyant.

They are up more than 9% in the past month of trade. One reason might be the underlying condition Resmed treats, in my opinion.

Brokers continue to highlight the vast potential market for ResMed, estimating an addressable market of more than 1 billion people.

Not only is this an enormous market to sell into, but it isn't sensitive to the business cycle. The number of home loans doesn't impact how many people have OSA, for instance.

This is a characteristic of high-quality ASX healthcare shares, in that they are defensive in times of volatility, as healthcare itself is a defensive sector.

Both Morgans and Macquarie mention this in their analyses.

Resmed shares takeaway

Experts say ResMed shares continue to be well-positioned for the future. Low competition, financial growth, and a strong market position are standout factors.

However, as always, remember to conduct your own due diligence and consult professional advice when needed.

Should you invest $1,000 in Resmed Inc. right now?

Before you buy Resmed Inc. shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Resmed Inc. wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man slumps crankily over his morning coffee as it pours with rain outside.
Earnings Results

This ASX healthcare stock is crashing 30% on half year results

Why is this stock crashing deep into the red today? Let's find out.

Read more »

Buy, hold and sell ratings written on signs on a wooden pole.
Healthcare Shares

CSL shares: Buy, sell or hold in 2025?

Three investment experts offer their view on the outlook for CSL shares.

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Earnings Results

Why has this ASX 200 healthcare stock crashed 24% in 2 days?

It has been a tough start to the week for this medical device company's shareholders.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

This little-known healthcare company is now the 17th-largest business in the ASX 200

This stock isn’t well-known, but it’s a market leader with significant potential.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why I think this ASX small-cap share is a buy at $1.18

After falling almost 17% over the past year, I see a lot of value at the current price.

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Healthcare Shares

Up 175% in 12 months: Bell Potter just upgraded this high-flying ASX 200 share

This share has smashed the market in recent times but the gains may not be over.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 25% on big UK news

Investors are sending this ASX healthcare stock rocketing on Friday. But why?

Read more »

two men shake hands on a deal.
Healthcare Shares

Can you guess which ASX 300 healthcare stock is rocketing 34% on takeover news

This share is rocketing on Friday after accepting a takeover offer.

Read more »